For example, Burchert et al. has reported that 75% of CML patients receiving IFN-α/imatinib combination therapy are able to stay in remission after discontinuing imatinib treatment [19], whereas a lower frequency (30–40%) of successful treatment discontinuations have been observed after imatinib monotherapy [22], [23]. Here, IFNA1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.